Received Apr 17, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| MENB | MENINGOCOCCAL B (BEXSERO) | NOVARTIS VACCINES AND DIAGNOSTICS | UNK | UNK | — |
| MNQ | MENINGOCOCCAL CONJUGATE (MENVEO) | NOVARTIS VACCINES AND DIAGNOSTICS | UNK | UNK | — |
Because of her inability to maintain antibodies she is re-vaccinated with Meningococcal vaccines; This non-serious case was reported by a physician via sales rep and described the occurrence of off label use in a adult female patient who received Men ACWY-CRM NVS (Menveo) for prophylaxis. Co-suspect products included Men B NVS (Bexsero) for prophylaxis. The patient's past medical history included dialysis (The patient also undergoes dialysis for treatment of this syndrome) and henoch-schonlein purpura. Concurrent medical conditions included autoimmune disorder. On an unknown date, the patient received Menveo and Bexsero. On an unknown date, an unknown time after receiving Menveo and Bexsero, the patient experienced off label use (Verbatim: Because of her inability to maintain antibodies she is re-vaccinated with Meningococcal vaccines). The outcome of the off label use was not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date : 08-APR-2025 Adult Female had an autoimmune syndrome. The syndrome ends in Purpura (possibly Henoch-Schonlein purpura). Over time her therapy to treat the syndrome had decreased her immune system's ability to maintain antibodies. The patient also undergoes dialysis for treatment of this syndrome. Because of her inability to maintain antibodies she was re-vaccinated with Meningococcal vaccines (unknown if Menveo or Bexsero or both) every 2 to 4 years which led to off label use.
Autoimmune disorder
Medical History/Concurrent Conditions: Dialysis (The patient also undergoes dialysis for treatment of this syndrome); Henoch-Schonlein purpura